Mumbai-based BDR Pharma has launched CABOZANTINIB to treat metastatic medullary thyroid cancer, advanced renal cell carcinoma and hepatocellular carcinoma.

BDR Pharma is amongst the first to receive permission from DCGI and launch the drug in India, which will be available in the market in the next few days.

The drug works by blocking (inhibiting) the signals inside cancer cells that make them grow and divide. In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, CABOZANIB is shown to have a better PFS (Progression-Free Survival).
 
Raheel Shah, Director – Business Development, BDR Pharmaceuticals, expressed: "Though we have been outstretched in all departments to deliver on Covid treatment on an emergency basis, we have not allowed this to hamper our efforts on other equally important priority segments, including oncology. We have ensured that all the other equally important segments, especially oncology, receive their priority tag, and all necessary allocations have been made accordingly. The result is the advent development of this new generic cancer molecule called "Cabozantinib (Cabozanib)."